PTPA and breast cancer: Thus, we evaluate the potential therapeutic value of PP2A activation using FTY720 to treat breast cancer cells and observed a significant decrease of cell growth and induction of caspase-dependent apoptosis in both MDA-MB-231 and BT-474 cells, in concordance with the FTY720-mediated antitumor properties previously reported [26, 31, 32].